Trial · NCT03805100
Adverse events152
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 152
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Conjunctival Haemorrhage | Eye disorders | Xlucane (Proposed Ranibizumab Biosimilar) | 15 | 292 | 19 |
| other | Conjunctival Haemorrhage | Eye disorders | Lucentis (Ranibizumab) | 16 | 290 | 22 |
| other | Hypertension | Vascular disorders | Xlucane (Proposed Ranibizumab Biosimilar) | 10 | 292 | 10 |
| other | Hypertension | Vascular disorders | Lucentis (Ranibizumab) | 17 | 290 | 19 |
| serious | Retinal pigment epithelial tear | Eye disorders | Xlucane (Proposed Ranibizumab Biosimilar) | 2 | 292 | 2 |
| serious | Retinal pigment epithelial tear | Eye disorders | Lucentis (Ranibizumab) | 1 | 290 | 2 |
| serious | Retinal Haemorrhage | Eye disorders | Xlucane (Proposed Ranibizumab Biosimilar) | 1 | 292 | 1 |
| serious | Retinal Haemorrhage | Eye disorders | Lucentis (Ranibizumab) | 1 | 290 | 1 |
| serious | Macular vasospasm | Eye disorders | Xlucane (Proposed Ranibizumab Biosimilar) | 1 | 292 | 1 |
| serious | Macular vasospasm | Eye disorders | Lucentis (Ranibizumab) | 0 | 290 | 0 |
| serious | Visual acuity reduced | Eye disorders | Xlucane (Proposed Ranibizumab Biosimilar) | 0 | 292 | 0 |
| serious | Visual acuity reduced | Eye disorders | Lucentis (Ranibizumab) | 1 | 290 | 1 |
| serious | Endophthalmitis | Eye disorders | Xlucane (Proposed Ranibizumab Biosimilar) | 0 | 292 | 0 |
| serious | Endophthalmitis | Eye disorders | Lucentis (Ranibizumab) | 1 | 290 | 1 |
| serious | COVID-19 | Infections and infestations | Xlucane (Proposed Ranibizumab Biosimilar) | 5 | 292 | 5 |
| serious | COVID-19 | Infections and infestations | Lucentis (Ranibizumab) | 1 | 290 | 1 |
| serious | Pneumonia | Infections and infestations | Xlucane (Proposed Ranibizumab Biosimilar) | 2 | 292 | 2 |
| serious | Pneumonia | Infections and infestations | Lucentis (Ranibizumab) | 1 | 290 | 1 |
| serious | Urinary tract infection | Infections and infestations | Xlucane (Proposed Ranibizumab Biosimilar) | 3 | 292 | 3 |
| serious | Urinary tract infection | Infections and infestations | Lucentis (Ranibizumab) | 0 | 290 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03805100/events